Here’s Why Snap Stock Is Moving

Snap Inc (NYSE: SNAP) shares are trading lower by around 2.84% to $10.43 Thursday morning. The stock is falling potentially on downward momentum after the company this week reported third-quarter earnings results.

Snap Inc (NYSE:SNAP) shares are trading lower by around 2.84% to $10.43 Thursday morning. The stock is falling potentially on downward momentum after the company this week reported third-quarter earnings results.

Snap also received a number of analyst rating updates following the earnings print.

What Happened?

Snap reported second-quarter revenue of $1.07 billion, which was down 4% year-over-year. The revenue total came in ahead of a Street consensus estimate of $1.05 billion.

The company reported a loss of two cents per share, which beat a Street estimate of a loss of four cents per share.

Snap ended the second quarter with 397 million daily active users, which was up 14% year-over-year. The company said daily active users were up sequentially and year-over-year for North America, Europe and the rest of the global regions…Read More

What Else?

Snap’s 4% year-over-year decline in revenue may concern investors, despite exceeding the Street consensus estimate. The overall decrease in revenue could signal challenges or weaker growth, leading to negative sentiment towards the stock.

However, positive aspects include improved engagement metrics, with daily active users in North America increasing sequentially for the first time since third-quarter 2022.

According to data from Benzinga Pro, SNAP has a 52-week high of $13.89 and a 52-week low of $7.33.

Total
0
Shares
Related Posts
Read More

IMV Announced Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S; IMV Expects Its Current Cash Position Will Be Sufficient To Fund Operations Into The Second Half of 2023

IMV Inc. (Nasdaq: IMV; TSX: IMV) today outlined its planned 2023 milestones to advance the clinical development of its lead therapeutic, maveropepimut-S (MVP-S). Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023

IMV